Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged artery.

The continuous glucose monitoring (CGM) system now connects to the weight management plan to help people living with diabetes understand how food and activity impact their glucose levels.

With the addition of the Alinity^® h-series, Abbott now has one of the broadest diagnostic offerings for laboratories.

Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA battery.

European study finds the Abbott CardioMEMS sensor results in improved quality of life and 44% reduction in heart failure hospitalizations.

TactiFlex Ablation Catheter, Sensor Enabled, is the world's first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation.

The device provides continuous monitoring for abnormal heart rhythms while offering tools designed to help improve data management and workflow within a physician's practice.

Data presented at EuroPCR 2023 build on prior study results demonstrating Abbott's TriClip is a safe and effective therapy to treat leaky tricuspid valves.

The FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic back pain when surgery is not an option.

The Eterna spinal cord stimulation (SCS) system is FDA approved for wider access to scans, allowing for more options for people in need of imaging.